{"prompt": "['R2810-ONC-1676 Amendment 7', 'Clinical Study Protocol', 'Endocrine Adverse Event Management (Cont)', 'Diagnostic', 'ENDOCRINE', 'REGN2810 Dosing', 'Action and Guidelines', 'Considerations', 'EVENTS', 'Management', 'CTCAE v4.03 Grade', 'Thyroid hormone and/or steroid replacement', 'therapy to manage adrenal insufficiency.', 'If Grade 1-2 hypophysitis is considered, pituitary', 'All attempts should', 'Hold until on stable', 'gland imaging should be considered (magnetic', 'be made to rule out', 'Grade 1-4', 'resonance imaging [MRIs] with gadolinium and', 'replacement dose', 'other causes such as', 'selective cuts of the pituitary can show', 'brain metastases,', 'Adrenal insufficiency', 'enlargement or heterogeneity and confirm the', 'sepsis, and/or', 'Hypophysitis', 'diagnosis).', 'infection. An', 'Hypopituitarism', 'Grade 3-4 hypophysitis with clinically significant', 'Pan-hypopituitarism', 'endocrinology', 'adrenal insufficiency and hypotension,', 'consultation is', 'dehydration, and electrolyte abnormalities (such', 'recommended', 'as hyponatremia and hyperkalemia) constitutes', 'adrenal crisis. Hospitalization and IV', 'methylprednisolone should be initiated.', 'Page 122 of 145', 'Regeneron Pharmaceuticals, Inc.', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Pneumonitis Adverse Event Management', 'PNEUMONITIS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Grade 1', 'Consider hold of', 'Radiologic findings should be followed on serial', 'Pneumonitis', 'Interstitial lung', 'therapy. REGN2810', 'imaging studies at least every 3 weeks.', 'disease', 'may be continued with', 'Monitor for symptoms every 2-3 days.', 'Acute interstitial', 'close monitoring.', 'Consider pulmonary consultation and/or', 'pneumonitis', 'bronchoscopy if clinically indicated.', 'To rule out other causes such as infection:', 'Consider pulmonary consultation with bronchoscopy and', 'All attempts should', 'biopsy/bronchoalveolar lavage (BAL).', 'be made to rule out', 'Consider pulmonary function tests.', 'Follow radiologic findings on serial imaging studies every', 'other causes such as', '1-3 days', 'metastatic disease,', 'If the patient is determined to have study drug associated', 'bacterial or viral', 'pneumonitis:', 'infection.', 'Monitor symptoms daily; consider hospitalization.', 'Grade 2', 'Hold REGN2810', 'Treat with systemic corticosteroids at a dose of 1-2 mg/kg/day', 'Pneumonitis', 'prednisone or equivalent. When symptoms improve to Grade', 'Interstitial lung', '1 or less, steroid taper should be started and continued over', 'no less than 4 weeks.', 'disease', 'Treatment with REGN2810 may be resumed if the event', 'Acute interstitial', 'improves to < Grade 1 within 12 weeks and corticosteroids', 'pneumonitis', 'have been reduced to the equivalent of methylprednisolone', '10 mg by mouth daily or less. Repeat chest imaging monthly', 'as clinically indicated.', 'For Grade 2 pneumonitis that improves to <Grade 1 within 12', 'weeks, the following rules should apply:', 'First episode of pneumonitis: May increase dosing interval by', 'one week in subsequent cycles.', 'Second episode of pneumonitis: Discontinue REGN2810 if', 'upon rechallenge the patient develops a second episode of', 'Grade 2 pneumonitis.', 'Regeneron Pharmaceuticals, Inc.', 'Page 123 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Pneumonitis Adverse Event Management (Cont)', 'PNEUMONITIS', 'REGN2810 Dosing', 'Diagnostic', 'Action and Guidelines', 'CTCAE v4.03 Grade', 'Management', 'Considerations', 'Consider pulmonary function tests with', 'pulmonary consult.', 'Bronchoscopy with biopsy and/or BAL is', 'recommended.', 'Treat with IV steroids (methylprednisolone 125', 'mg). When symptoms improve to grade 1 or less,', 'a high-dose oral steroid (prednisone 1-2 mg/kg', 'All attempts should', 'once per day or dexamethasone 4 mg every 4', 'be made to rule out', 'Grade 3-4', 'Discontinue REGN2810', 'hours) taper should be started and continued over', 'other causes such as', 'Pneumonitis', 'no less than 4 weeks.', 'metastatic disease,', 'Interstitial lung', 'Add prophylactic antibiotics for opportunistic', 'bacterial or viral', 'disease', 'infections', 'infection.', 'Acute interstitial', 'pneumonitis', 'If IV steroids followed by high-dose oral steroids', 'does not reduce initial symptoms within 48-72', 'hours, treat with infliximab at 5 mg/kg once every', '2 weeks. Discontinue infliximab upon symptom', 'relief and initiate a prolonged steroid taper over', '45-60 days. If symptoms worsen during steroid', 'reduction, initiate a retapering of steroids starting', 'at a higher dose of 80 or 100 mg followed by a', 'more prolonged taper and administer infliximab.', 'Regeneron Pharmaceuticals, Inc.', 'Page 124 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.0 Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}